Evidence map›Paper›PMID 40456944›Full record

ArticleAAPS PharmSciTech2025

Injectable PLGA-based In Situ Forming Subconjunctival Implant for Sustained Ocular Delivery of Ketotifen Fumarate: Formulation, Drug Release, and Biocompatibility Studies.

Nur Mita, Xuejia Kang, Pengyu Chen, Oladiran Fasina, Shenise Howard, Anna-Catherine Bowden, Richard J McMullen, Amol Suryawanshi, R Jayachandra Babu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in AAPS PharmSciTech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Nur MitaDepartment of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, AL, 36849, United States of America.
Xuejia KangDepartment of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, AL, 36849, United States of America.
Pengyu ChenMaterials Research and Education Center, Materials Engineering, Department of Mechanical Engineering, Auburn University, Auburn, AL, 36849, United States of America.
Oladiran FasinaDepartment of Biosystems Engineering, Samuel Ginn College of Engineering, Auburn University, Auburn, AL, 36849, United States of America.
Shenise HowardDepartment of Clinical Sciences, College of Veterinary Medicine, Auburn University, Auburn, AL, 36849, United States of America.
Anna-Catherine BowdenDepartment of Clinical Sciences, College of Veterinary Medicine, Auburn University, Auburn, AL, 36849, United States of America.
Richard J McMullenDepartment of Clinical Sciences, College of Veterinary Medicine, Auburn University, Auburn, AL, 36849, United States of America.
Amol SuryawanshiDepartment of Population Health and Pathobiology, College of Veterinary Medicine, North Carolina State University, Raleigh, NC, United States of America.
R Jayachandra BabuDepartment of Drug Discovery and Development, Harrison College of Pharmacy, Auburn University, Auburn, AL, 36849, United States of America. ramapjb@auburn.edu.ORCID http://orcid.org/0000-0003-0337-2291

Funding

Targeting anti-viral and anti-inflammatory responses during ocular HSV-1 infection to prevent vision impairment.R15EY035057 · NEI · AUBURN UNIVERSITY AT AUBURN · PI RAMAPURAM, JAYACHANDRA B · 2023 to 2023
$453k
NEI NIH HHS R15 EY035057
6 · The paper itself

Abstract

Ketotifen fumarate is very effective in treating ocular conditions like allergic conjunctivitis. However, its clinical effectiveness is limited by rapid washout, frequent dosing, and poor bioavailability. This study developed a ketotifen fumarate-loaded in situ forming subconjunctival injectable implant (ISFSI) for use in large animal species such as horses and alpacas. ISFSIs were formulated by dispersing ketotifen fumarate in polylactide-co-glycolide (PLGA) combined with different release retarders (Kolliphor

Indexed as

KetotifenLactic AcidPolyglycolic AcidAdministration, OphthalmicAnimalsBiocompatible MaterialsCell LineChemistry, PharmaceuticalConjunctivaDelayed-Action PreparationsDrug Delivery SystemsDrug ImplantsDrug LiberationHumansPolylactic Acid-Polyglycolic Acid CopolymerViscosityBiocompatible MaterialsDelayed-Action PreparationsDrug ImplantsKetotifenLactic AcidPolyglycolic AcidPolylactic Acid-Polyglycolic Acid Copolymerin situ forming subconjunctival implantketotifen fumaratePLGA

Identifiers

PMID40456944
PMCPMC13495649

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.